Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain

Article activity feed

1. Version published to 10.1016/j.jcv.2022.105130

   Apr 1, 2022
2. 

   ScreenIT

   Mar 15, 2021

   SciScore for 10.1101/2021.03.11.21253142: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The Institutional Review Board of the Instituto de Salud Carlos III approved the study. Consent: Written informed consent was obtained from all participants.
   Randomization	Briefly, 1,500 census tracts, with up to 24 households per tract, were randomly selected via two-stage sampling stratified by province and municipality size.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   General study design and ENE-COVID study population: The ENE-COVID study is a nationwide, population-based cohort study of sero-prevalence, the general objectives of which were to i) estimate the …

   SciScore for 10.1101/2021.03.11.21253142: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The Institutional Review Board of the Instituto de Salud Carlos III approved the study. Consent: Written informed consent was obtained from all participants.
   Randomization	Briefly, 1,500 census tracts, with up to 24 households per tract, were randomly selected via two-stage sampling stratified by province and municipality size.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   General study design and ENE-COVID study population: The ENE-COVID study is a nationwide, population-based cohort study of sero-prevalence, the general objectives of which were to i) estimate the prevalence of COVID-19 in the community-dwelling population of Spain by monitoring antibodies against SARS-CoV-2, and ii) evaluate evolutionary trends of antibodies over time.	SARS-CoV-2 suggested: None
   Software and Algorithms
   Sentences	Resources
   The SARS-CoV-2 IgG CMIA (Abbott Laboratories, Illinois, USA) allows qualitative detection of IgG directed against the nucleocapsid using serum obtained from venipuncture blood.	Abbott Laboratories suggested: None
   The present study reports immunoassay serology results obtained using both the Abbott and Beckman assays.	Abbott suggested: (Abbott, RRID:SCR_010477)
   Statistical analyses were performed using GraphPad Prism software v.7.02	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)
   GraphPad Software Inc.	GraphPad suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.03.11.21253142 on medRxiv

   Mar 12, 2021